CGRP Inhibitor Market (2023 Edition): Analysis By Treatment (Preventive, Acute), Route of Administration (Oral, Nasal, Intravenous), By End-User, By Region, By Country: Market Insights and Forecast (2019-2029)

Report
230 Pages
September 2023
Region: Global
Azoth Analytics
ID: 5871176

The research report titled “Global CGRP Inhibitor Market (2023 Edition)” provides a complete analysis of the Global CGRP Inhibitor industry in terms of market segmentation By Treatment (Preventive, Acute), By Route of Administration (Oral, Nasal, Intravenous), By End-User (Hospitals, Pharmacies, Specialty Clinics), By Region (Americas, Europe, Asia-pacific, Middle-East & Africa), for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029.

The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, United Kingdom, Germany, France, Italy, Spain, China, Japan, South Korea). Additionally, the research report presents data including market size, yearly growth and potential analysis, the competitive study of market players, investment opportunities and demand forecast. The research report also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

The Global CGRP Inhibitor Market is expected to generate USD 5.6 billion by the end of 2029, up from USD 1.5 billion in 2022. A favourable growth element for the global CGRP Inhibitor market is the growing demand for target therapies, the high prevalence of migraine and the unmet medical requirement of migraine care. During the forecast period, 2024-2029, Global CGRP Inhibitor is expected to expand at a CAGR of 21%. High-throughput screening, genomics, and bioinformatics technologies have enabled rapid identification and validation of potential drug targets, such as the CGRP pathway. These technologies expedited the discovery of CGRP as a key player in migraine pathophysiology. They facilitated the identification of the CGRP receptor as a potential therapeutic target for the development of CGRP inhibitors.

CGRP inhibitors have prompted a paradigm shift in migraine treatment, transitioning from predominantly acute symptom relief to preventive management. This shift aligns with the broader healthcare trend of focusing on proactive and preventive care to enhance patient well-being. By offering an option for preventing migraine attacks, CGRP inhibitors provide patients with a greater degree of control over their condition, reducing the need for reactive interventions and emergency care.

The Intravenous segment is gaining widespread acceptance owing to the quickest onset of action in the Intravenous route since the drug is directly delivered into the bloodstream. This could be beneficial for severe, acute migraine attacks. Additionally, some patients may have difficulty administering subcutaneous injections themselves or may prefer to have medical professionals administer the medication. In such cases, hospitals could play a role in providing intravenous CGRP inhibitors.

The development and commercialisation of CGRP inhibitors showcase pharmaceutical innovation at its finest. The discovery of CGRP's pivotal role in migraine pathophysiology and the subsequent design of targeted inhibitors highlights the industry's commitment to advancing patient care. This innovation extends beyond drug development to encompass novel drug delivery methods, formulations, and dosing regimens that enhance patient convenience and adherence.

Advancements in understanding the genetic and physiological underpinnings of migraine have paved the way for personalized medicine approaches. CGRP inhibitors exemplify this trend by enabling healthcare providers to tailor treatment plans based on individual patient profiles, preferences, and responsiveness. This personalized approach enhances treatment outcomes and patient satisfaction, driving demand for CGRP inhibitors.

Introducing CGRP inhibitors for new indications such as other headache disorders, pain conditions, or neurological disorders can broaden the market reach of these medications, tapping into previously untapped patient populations. As research continues to uncover the role of CGRP in various physiological processes, the potential for expanding CGRP inhibitors to new indications remains an exciting opportunity for both pharmaceutical companies and patients.

Scope of the Report

The report analyses the CGRP Inhibitor Market by Value (USD Million).
The report presents the analysis of CGRP Inhibitor Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
The report analyses the CGRP Inhibitor Market by Treatment (Preventive, Acute).
The report analyses the CGRP Inhibitor Market by Route of Administration (Oral, Nasal, Intravenous).
The report analyses the CGRP Inhibitor Market by End-User (Hospitals, Pharmacies, Specialty Clinics).
The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by services, by mode of operation & by end users.
Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Eli Lilly and Company, Pfizer, Teva Pharmaceuticals, Lundbeck, AbbVie Inc., Amgen Inc. and Novartis.

1. Market Background

1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology

2. Strategic Recommendations

2.1 The development of biosimilar and generic versions of existing CGRP inhibitors
2.2 Use of CGRP inhibitors to new indications beyond migraine treatment

3. Global CGRP Inhibitor Market: Historic and Forecast (2019-2029)

3.1 CGRP Inhibitor studies in pipeline
3.2 Prevalence of Migraine, 2019 (in Millions)
3.3 Migraine : Fact Sheet
3.4 Global CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
3.5 Degree of Impact of Covid-19 on CGRP Inhibitor Market
3.6 Global CGRP Inhibitor Market Segmentation : By Treatment
3.6.1 Global CGRP Inhibitor Market, By Treatment Overview
3.6.2 Global CGRP Inhibitor Market Size, By Preventive, By Value, 2019H-2029F (USD Million & CAGR)
3.6.3 Global CGRP Inhibitor Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
3.7 Global CGRP Inhibitor Market Segmentation: By Route of Administration
3.7.1 Global CGRP Inhibitor Market, By Route of Administration Overview
3.7.2 Global CGRP Inhibitor Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
3.7.3 Global CGRP Inhibitor Market Size, By Nasal, By Value, 2019H-2029F (USD Million & CAGR)
3.7.4 Global CGRP Inhibitor Market Size, By Intravenous, By Value, 2019H-2029F (USD Million & CAGR)
3.8 Global CGRP Inhibitor Market Segmentation: By End-User
3.8.1 Global CGRP Inhibitor Market, By End-User Overview
3.8.2 Global CGRP Inhibitor Market Size, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)
3.8.3 Global CGRP Inhibitor Market Size, By Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
3.8.4 Global CGRP Inhibitor Market Size, By Specialty Clinics, By Value, 2019H-2029F (USD Million & CAGR)

4. Global CGRP Inhibitor Market, Regional Analysis

4.1 Regional Coverage of the Study
4.2 Regional Snapshot

5. Americas CGRP Inhibitor Market: Historic and Forecast (2019-2029)

5.1 Americas CGRP Inhibitor Market: Snapshot
5.2 Americas CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.3 Americas CGRP Inhibitor Market: Key Factors
5.4 Americas CGRP Inhibitor Market Segmentation: By Treatment
5.4.1 Americas CGRP Inhibitor Market, By Treatment Overview
5.4.2 Americas CGRP Inhibitor Market Size, By Preventive, By Value, 2019H-2029F (USD Million & CAGR)
5.4.3 Americas CGRP Inhibitor Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
5.4 Americas CGRP Inhibitor Market Segmentation: By Route of Administration
5.4.1 Americas CGRP Inhibitor Market, By Route of Administration Overview
5.4.2 Americas CGRP Inhibitor Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
5.4.3 Americas CGRP Inhibitor Market Size, By Nasal, By Value, 2019H-2029F (USD Million & CAGR)
5.4.4 Americas CGRP Inhibitor Market Size, By Intravenous, By Value, 2019H-2029F (USD Million & CAGR)
5.5 Americas CGRP Inhibitor Market Segmentation: By End-User
5.5.1 Americas CGRP Inhibitor Market, By End-User Overview
5.5.2 Americas CGRP Inhibitor Market Size, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)
5.5.3 Americas CGRP Inhibitor Market Size, By Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
5.5.4 Americas CGRP Inhibitor Market Size, By Specialty Clinics, By Value, 2019H-2029F (USD Million & CAGR)
5.6 Americas CGRP Inhibitor Market Segmentation : By Country
5.6.1 Americas CGRP Inhibitor Market, By Country Overview
5.6.2 United States CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.6.2.1 United States CGRP Inhibitor Market, By Treatment
5.6.2.2 United States CGRP Inhibitor Market, By Route of Administration
5.6.2.3 United States CGRP Inhibitor Market, By End-User
5.6.3 Canada CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.6.3.1 Canada CGRP Inhibitor Market, By Treatment
5.6.2.2 Canada CGRP Inhibitor Market, By Route of Administration
5.6.3.3 Canada CGRP Inhibitor Market, By End-User
5.6.4 Rest of Americas CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.6.4.1 Rest of Americas CGRP Inhibitor Market, By Treatment
5.6.4.2 Rest of Americas CGRP Inhibitor Market, By Route of Administration
5.6.4.4 Rest of Americas CGRP Inhibitor Market, By End-User

6. Europe CGRP Inhibitor Market: Historic and Forecast (2019-2029)

6.1 Europe CGRP Inhibitor Market: Snapshot
6.2 Europe CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.3 Europe CGRP Inhibitor Market: Key Factors
6.4 Europe CGRP Inhibitor Market Segmentation: By Treatment
6.4.1 Europe CGRP Inhibitor Market, By Treatment Overview
6.4.2 Europe CGRP Inhibitor Market Size, By Preventive, By Value, 2019H-2029F (USD Million & CAGR)
6.4.3 Europe CGRP Inhibitor Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
6.5 Europe CGRP Inhibitor Market Segmentation: By Route of Administration
6.5.1 Europe CGRP Inhibitor Market, By Route of Administration Overview
6.5.2 Europe CGRP Inhibitor Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
6.5.3 Europe CGRP Inhibitor Market Size, By Nasal, By Value, 2019H-2029F (USD Million & CAGR)
6.5.4 Europe CGRP Inhibitor Market Size, By Intravenous, By Value, 2019H-2029F (USD Million & CAGR)
6.6 Europe CGRP Inhibitor Market Segmentation: By End-User
6.6.1 Europe CGRP Inhibitor Market, By End-User Overview
6.6.2 Europe CGRP Inhibitor Market Size, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)
6.6.3 Europe CGRP Inhibitor Market Size, By Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
6.6.4 Europe CGRP Inhibitor Market Size, By Specialty Clinics, By Value, 2019H-2029F (USD Million & CAGR)
6.7 Europe CGRP Inhibitor Market Segmentation: By Country
6.7.1 Europe CGRP Inhibitor Market, By Country Overview
6.7.2 Germany CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.2.1 Germany CGRP Inhibitor Market, By Treatment
6.7.2.2 Germany CGRP Inhibitor Market, By Route of Administration
6.7.2.3 Germany CGRP Inhibitor Market, By End-User
6.7.3 United Kingdom CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.3.1 United Kingdom CGRP Inhibitor Market, By Treatment
6.7.3.2 United Kingdom CGRP Inhibitor Market, By Route of Administration
6.7.3.2 United Kingdom CGRP Inhibitor Market, By End-User
6.7.4 France CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.4.1 France CGRP Inhibitor Market, By Treatment
6.7.4.2 France CGRP Inhibitor Market, By Route of Administration
6.7.4.3 France CGRP Inhibitor Market, By End-User
6.7.5 Italy CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.5.1 Italy CGRP Inhibitor Market, By Treatment
6.7.5.2 Italy CGRP Inhibitor Market, By Route of Administration
6.7.5.3 Italy CGRP Inhibitor Market, By End-User
6.7.6 Spain CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.6.1 Spain CGRP Inhibitor Market, By Treatment
6.7.6.2 Spain CGRP Inhibitor Market, By Route of Administration
6.7.6.3 Spain CGRP Inhibitor Market, By End-User
6.7.7 Rest of Europe CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.7.1 Rest of Europe CGRP Inhibitor Market, By Treatment
6.7.7.2 Rest of Europe CGRP Inhibitor Market, By Route of Administration
6.7.7.3 Rest of Europe CGRP Inhibitor Market, By End-User

7. Asia Pacific CGRP Inhibitor Market: Historic and Forecast (2019-2029)

7.1 Asia Pacific CGRP Inhibitor Market: Snapshot
7.2 Asia Pacific CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.3 Asia Pacific CGRP Inhibitor Market: Key Factors
7.4 Asia Pacific CGRP Inhibitor Market Segmentation: By Treatment
7.4.1 Asia Pacific CGRP Inhibitor Market, By Treatment Overview
7.4.2 Asia Pacific CGRP Inhibitor Market Size, By Preventive, By Value, 2019H-2029F (USD Million & CAGR)
7.4.3 Asia Pacific CGRP Inhibitor Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
7.5 Asia Pacific CGRP Inhibitor Market Segmentation: By Route of Administration
7.5.1 Asia Pacific CGRP Inhibitor Market, By Route of Administration Overview
7.5.2 Asia Pacific CGRP Inhibitor Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
7.5.3 Asia Pacific CGRP Inhibitor Market Size, By Nasal, By Value, 2019H-2029F (USD Million & CAGR)
7.5.4 Asia Pacific CGRP Inhibitor Market Size, By Intravenous, By Value, 2019H-2029F (USD Million & CAGR)
7.6 Asia Pacific CGRP Inhibitor Market Segmentation: By End-User
7.6.1 Asia Pacific CGRP Inhibitor Market, By End-User Overview
7.6.2 Asia Pacific CGRP Inhibitor Market Size, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)
7.6.3 Asia Pacific CGRP Inhibitor Market, By Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
7.6.4 Asia Pacific CGRP Inhibitor Market, By Specialty Clinics, By Value, 2019H-2029F (USD Million & CAGR)
7.7 Asia Pacific CGRP Inhibitor Market Segmentation: By Country
7.7.1 Asia Pacific CGRP Inhibitor Market, By Country Overview
7.7.2 China CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.7.2.1 China CGRP Inhibitor Market, By Treatment
7.7.2.2 China CGRP Inhibitor Market, By Route of Administration
7.7.2.3 China CGRP Inhibitor Market, By End-User
7.7.3 Japan CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.7.3.1 Japan CGRP Inhibitor Market, By Treatment
7.7.3.2 Japan CGRP Inhibitor Market, By Route of Administration
7.7.3.3 Japan CGRP Inhibitor Market, By End-User
7.7.4 South Korea CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.7.4.1 South Korea CGRP Inhibitor Market, By Treatment
7.7.4.2 South Korea CGRP Inhibitor Market, By Route of Administration
7.7.4.3 South Korea CGRP Inhibitor Market, By End-User
7.7.5 Rest of Asia Pacific CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.7.5.1 Rest of Asia Pacific CGRP Inhibitor Market, By Treatment
7.7.5.2 Rest of Asia Pacific CGRP Inhibitor Market, By Route of Administration
7.7.5.3 Rest of Asia Pacific CGRP Inhibitor Market, By End-User

8. Middle East & Africa CGRP Inhibitor Market: Historic and Forecast (2019-2029)

8.1 Middle East and Africa CGRP Inhibitor Market: Snapshot
8.2 Middle East and Africa CGRP Inhibitor Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
8.3 Middle East and Africa CGRP Inhibitor Market: Key Factors
8.4 Middle East and Africa CGRP Inhibitor Market Segmentation: By Treatment
8.4.1 Middle East and Africa CGRP Inhibitor Market, By Treatment Overview
8.4.2 Middle East and Africa CGRP Inhibitor Market Size, By Preventive, By Value, 2019H-2029F (USD Million & CAGR)
8.4.3 Middle East and Africa CGRP Inhibitor Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
8.5 Middle East and Africa CGRP Inhibitor Market Segmentation: By Route of Administration
8.5.1 Middle East and Africa CGRP Inhibitor Market, By Route of Administration Overview
8.5.2 Middle East and Africa CGRP Inhibitor Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
8.5.3 Middle East and Africa CGRP Inhibitor Market Size, By Nasal, By Value, 2019H-2029F (USD Million & CAGR)
8.5.4 Middle East and Africa CGRP Inhibitor Market Size, By Intravenous, By Value, 2019H-2029F (USD Million & CAGR)
8.6 Middle East and Africa CGRP Inhibitor Market Segmentation: By End-User
8.6.1 Middle East and Africa CGRP Inhibitor Market, By End-User Overview
8.6.2 Middle East and Africa CGRP Inhibitor Market Size, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)
8.6.3 Middle East and Africa CGRP Inhibitor Market, By Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
8.6.4 Middle East and Africa CGRP Inhibitor Market, By Specialty Clinics, By Value, 2019H-2029F (USD Million & CAGR)

9. Market Dynamics

9.1 Impact assessment of Market Dynamics on Global CGRP Inhibitor Market
9.2 Drivers
9.3 Restraints
9.4 Trends

10. Industry Ecosystem Analysis

10.1 Porter Analysis

11. Competitive Landscape

11.1 Companies’ Product Positioning
11.2 Market Share of Leading Companies
11.3 List of CGRP Inhibitor Drugs
11.4 Company Profiling
11.4.1 Eli Lilly and Company
11.4.2 Pfizer
11.4.3 Teva Pharmaceutical
11.4.4 Lundbeck
11.4.5 AbbVie Inc.
11.4.6 Novartis
11.4.7 Amgen, INC.

List of Figures

Figure 1: Prevalence of Migraine, 2019 (in Millions)
Figure 2: Global CGRP Inhibitor Market Size, By Value, 2019-2022 (USD Million)
Figure 3: Global CGRP Inhibitor Market Size, By Value, 2023-2029 (USD Million)
Figure 4: Global CGRP Inhibitor Market Share, By Route of Administration, 2022 (%)
Figure 5: Global CGRP Inhibitor Market Size, By Preventive, By Value, 2019H-2029F (USD Million & CAGR)
Figure 6: Global CGRP Inhibitor Market Absolute Opportunity, By Preventive, 2019H-2029F (USD Million)
Figure 7: Global CGRP Inhibitor Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
Figure 8: Global CGRP Inhibitor Market Absolute Opportunity, By Acute, 2019H-2029F (USD Million)
Figure 9: Global CGRP Inhibitor Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
Figure 10: Global CGRP Inhibitor Market Absolute Opportunity, By Oral, 2019H-2029F (USD Million)
Figure 11: Global CGRP Inhibitor Market Size, By Nasal, By Value, 2019H-2029F (USD Million & CAGR)
Figure 12: Global CGRP Inhibitor Market Absolute Opportunity, By Nasal, 2019H-2029F (USD Million)
Figure 13: Global CGRP Inhibitor Market Size, By Intravenous, By Value, 2019H-2029F (USD Million & CAGR)
Figure 14: Global CGRP Inhibitor Market Absolute Opportunity, By Intravenous, 2019H-2029F (USD Million)
Figure 15: Global CGRP Inhibitor Market Size, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)
Figure 16: Global CGRP Inhibitor Market Absolute Opportunity, By Hospitals, 2019H-2029F (USD Million)
Figure 17: Global CGRP Inhibitor Market Size, By Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 18: Global CGRP Inhibitor Market Absolute Opportunity, By Pharmacies, 2019H-2029F (USD Million)
Figure 19: Global CGRP Inhibitor Market Size, By Specialty Clinics, By Value, 2019H-2029F (USD Million & CAGR)
Figure 20: Global CGRP Inhibitor Market Absolute Opportunity, By Specialty Clinics, 2019H-2029F (USD Million)
Figure 21: Americas CGRP Inhibitor Market Size, By Value, 2019H-2029F (USD Million)
Figure 22: Americas CGRP Inhibitor Market Share, By Route of Administration, 2022 (%)
Figure 23: Americas CGRP Inhibitor Market, By Preventive, By Value, 2019H-2029F (USD Million & CAGR)
Figure 24: Americas CGRP Inhibitor Market, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
Figure 25: Americas CGRP Inhibitor Market, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
Figure 26: Americas CGRP Inhibitor Market, By Nasal, By Value, 2019H-2029F (USD Million & CAGR)
Figure 27: Americas CGRP Inhibitor Market, By Intravenous, By Value, 2019H-2029F (USD Million & CAGR)
Figure 28: Americas CGRP Inhibitor Market, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)
Figure 29: Americas CGRP Inhibitor Market, By Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 30: Americas CGRP Inhibitor Market, By Specialty Clinics, By Value, 2019H-2029F (USD Million & CAGR)
Figure 31: United States CGRP Inhibitor Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 32: United States CGRP Inhibitor Market Value, By Route of Administration, 2022 (USD Million)
Figure 33: United States CGRP Inhibitor Market Share, By Treatment, By Value, 2022 (%)
Figure 34: United States CGRP Inhibitor Market Share, By Route of Administration, By Value, 2022 (%)
Figure 35: United States CGRP Inhibitor Market Share, By End-User, By Value, 2022 (%)
Figure 36: Canada CGRP Inhibitor Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 37: Canada CGRP Inhibitor Market Value, By Route of Administration,, 2022 (USD Million)
Figure 38: Canada CGRP Inhibitor Market Share, By Treatment, By Value, 2022 (%)
Figure 39: Canada CGRP Inhibitor Market Share, By Route of Administration, By Value, 2022 (%)
Figure 40: Canada CGRP Inhibitor Market Share, By End-User, By Value, 2022 (%)
Figure 41: Rest of Americas CGRP Inhibitor Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 42: Rest of Americas CGRP Inhibitor Market Value, By Route of Administration,, 2022 (USD Million)
Figure 43: Rest of Americas CGRP Inhibitor Market Share, By Treatment, By Value, 2022 (%)
Figure 44: Rest of Americas CGRP Inhibitor Market Share, By Route of Administration, By Value, 2022 (%)
Figure 45: Rest of Americas CGRP Inhibitor Market Share, By End-User, By Value, 2022 (%)
Figure 46: Europe CGRP Inhibitor Market Size, By Value, 2019H-2029F (USD Million)
Figure 47: Europe CGRP Inhibitor Market Share, By Route of Administration, 2022 (%)
Figure 48: Europe CGRP Inhibitor Market, By Preventive, By Value, 2019H-2029F (USD Million & CAGR)
Figure 49: Europe CGRP Inhibitor Market, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
Figure 50: Europe CGRP Inhibitor Market, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
Figure 51: Europe CGRP Inhibitor Market, By Nasal, By Value, 2019H-2029F (USD Million & CAGR)
Figure 52: Europe CGRP Inhibitor Market, By Intravenous, By Value, 2019H-2029F (USD Million & CAGR)
Figure 53: Europe CGRP Inhibitor Market, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)
Figure 54: Europe CGRP Inhibitor Market, By Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 55: Europe CGRP Inhibitor Market, By Specialty Clinics, By Value, 2019H-2029F (USD Million & CAGR)
Figure 56: Germany CGRP Inhibitor Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 57: Germany CGRP Inhibitor Market Value, By Route of Administration, 2022 (USD Million)
Figure 58: Germany CGRP Inhibitor Market Share, By Treatment, By Value, 2022 (%)
Figure 59: Germany CGRP Inhibitor Market Share, By Route of Administration, By Value, 2022 (%)
Figure 60: Germany CGRP Inhibitor Market Share, By End-User, By Value, 2022 (%)
Figure 61: United Kingdom CGRP Inhibitor Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 62: United Kingdom CGRP Inhibitor Market Value, By Route of Administration, 2022 (USD Million)
Figure 63: United Kingdom CGRP Inhibitor Market Share, By Treatment, By Value, 2022 (%)
Figure 64: United Kingdom CGRP Inhibitor Market Share, By Route of Administration, By Value, 2022 (%)
Figure 65: United Kingdom CGRP Inhibitor Market Share, By End-User, By Value, 2022 (%)
Figure 66: France CGRP Inhibitor Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 67: France CGRP Inhibitor Market Value, By Route of Administration, 2022 (USD Million)
Figure 68: France CGRP Inhibitor Market Share, By Treatment, By Value, 2022 (%)
Figure 69: France CGRP Inhibitor Market Share, By Route of Administration, By Value, 2022 (%)
Figure 70: France CGRP Inhibitor Market Share, By End-User, By Value, 2022 (%)
Figure 71: Italy CGRP Inhibitor Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 72: Italy CGRP Inhibitor Market Value, By Route of Administration, 2022 (USD Million)
Figure 73: Italy CGRP Inhibitor Market Share, By Treatment, By Value, 2022 (%)
Figure 74: Italy CGRP Inhibitor Market Share, By Route of Administration, By Value, 2022 (%)
Figure 75: Italy CGRP Inhibitor Market Share, By End-User, By Value, 2022 (%)
Figure 76: Spain CGRP Inhibitor Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 77: Spain CGRP Inhibitor Market Value, By Route of Administration, 2022 (USD Million)
Figure 78: Spain CGRP Inhibitor Market Share, By Treatment, By Value, 2022 (%)
Figure 79: Spain CGRP Inhibitor Market Share, By Route of Administration, By Value, 2022 (%)
Figure 80: Spain CGRP Inhibitor Market Share, By End-User, By Value, 2022 (%)
Figure 81: Rest of Europe CGRP Inhibitor Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 82: Rest of Europe CGRP Inhibitor Market Value, By Route of Administration, 2022 (USD Million)
Figure 83: Rest of Europe CGRP Inhibitor Market Share, By Treatment, By Value, 2022 (%)
Figure 84: Rest of Europe CGRP Inhibitor Market Share, By Route of Administration, By Value, 2022 (%)
Figure 85: Rest of Europe CGRP Inhibitor Market Share, By End-User, By Value, 2022 (%)
Figure 86: Asia-Pacific CGRP Inhibitor Market Size, By Value, 2019H-2029F (USD Million)
Figure 87: Asia-Pacific CGRP Inhibitor Market Share, By Route of Administration, 2022 (%)
Figure 88: Asia-Pacific CGRP Inhibitor Market, By Preventive, By Value, 2019H-2029F (USD Million & CAGR)
Figure 89: Asia-Pacific CGRP Inhibitor Market, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
Figure 90: Asia-Pacific CGRP Inhibitor Market, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
Figure 91: Asia-Pacific CGRP Inhibitor Market, By Nasal, By Value, 2019H-2029F (USD Million & CAGR)
Figure 92: Asia-Pacific CGRP Inhibitor Market, By Intravenous, By Value, 2019H-2029F (USD Million & CAGR)
Figure 93: Asia-Pacific CGRP Inhibitor Market, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)
Figure 94: Asia-Pacific CGRP Inhibitor Market, By Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 95: Asia-Pacific CGRP Inhibitor Market, By Specialty Clinics, By Value, 2019H-2029F (USD Million & CAGR)
Figure 96: China CGRP Inhibitor Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 97: China CGRP Inhibitor Market Value, By Route of Administration, 2022 (USD Million)
Figure 98: China CGRP Inhibitor Market Share, By Treatment, By Value, 2022 (%)
Figure 99: China CGRP Inhibitor Market Share, By Route of Administration, By Value, 2022 (%)
Figure 100: China CGRP Inhibitor Market Share, By End-User, By Value, 2022 (%)
Figure 101: Japan CGRP Inhibitor Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 102: Japan CGRP Inhibitor Market Value, By Route of Administration, 2022 (USD Million)
Figure 103: Japan CGRP Inhibitor Market Share, By Treatment, By Value, 2022 (%)
Figure 104: Japan CGRP Inhibitor Market Share, By Route of Administration, By Value, 2022 (%)
Figure 105: Japan CGRP Inhibitor Market Share, By End-User, By Value, 2022 (%)
Figure 106: South Korea CGRP Inhibitor Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 107: South Korea CGRP Inhibitor Market Value, By Route of Administration, 2022 (USD Million)
Figure 108: South Korea CGRP Inhibitor Market Share, By Treatment, By Value, 2022 (%)
Figure 109: South Korea CGRP Inhibitor Market Share, By Route of Administration, By Value, 2022 (%)
Figure 110: South Korea CGRP Inhibitor Market Share, By End-User, By Value, 2022 (%)
Figure 111: Rest of Asia-Pacific CGRP Inhibitor Market, By Value, 2019H-2029F (USD Million & CAGR)
Figure 112: Rest of Asia-Pacific CGRP Inhibitor Market Value, By Route of Administration, 2022 (USD Million)
Figure 113: Rest of Asia-Pacific CGRP Inhibitor Market Share, By Treatment, By Value, 2022 (%)
Figure 114: Rest of Asia-Pacific CGRP Inhibitor Market Share, By Route of Administration, By Value, 2022 (%)
Figure 115: Rest of Asia-Pacific CGRP Inhibitor Market Share, By End-User, By Value, 2022 (%)
Figure 116: Middle East and Africa CGRP Inhibitor Market Size, By Value, 2019H-2029F (USD Million)
Figure 117: Middle East and Africa CGRP Inhibitor Market Share, By Route of Administration, 2022 (%)
Figure 118: Middle East and Africa CGRP Inhibitor Market, By Preventive, By Value, 2019H-2029F (USD Million & CAGR)
Figure 119: Middle East and Africa CGRP Inhibitor Market, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
Figure 120: Middle East and Africa CGRP Inhibitor Market, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
Figure 121: Middle East and Africa CGRP Inhibitor Market, By Nasal, By Value, 2019H-2029F (USD Million & CAGR)
Figure 122: Middle East and Africa CGRP Inhibitor Market, By Intravenous, By Value, 2019H-2029F (USD Million & CAGR)
Figure 123: Middle East and Africa CGRP Inhibitor Market, By Hospitals, By Value, 2019H-2029F (USD Million & CAGR)
Figure 124: Middle East and Africa CGRP Inhibitor Market, By Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 125: Middle East and Africa CGRP Inhibitor Market, By Specialty Clinics, By Value, 2019H-2029F (USD Million & CAGR)
Figure 126: Global Impact of Drivers and Restraints
Figure 127: Market Share of Prominent Companies of CGRP Inhibitor, 2022 (%)
Figure 128: Eli Lilly and Company Revenues, 2020-2022 (USD Million)
Figure 129: Eli Lilly and Company Revenues, By Geographic Segments, 2022 (%)
Figure 130: Eli Lilly and Company Revenue, By Therapeutic Area, 2022 (%)
Figure 131: Pfizer Revenues, 2020-2022 (USD Million)
Figure 132: Pfizer Revenues, By Business Segments, 2022 (%)
Figure 133: Pfizer Inc. Revenue, By Geographical Segments, 2022 (%)
Figure 134: Teva Pharmaceuticals Revenues, 2020-2022 (USD Million)
Figure 135: Teva Pharmaceuticals Revenue, By Geographical Segments, 2022 (%)
Figure 136: Lundbeck Revenues, 2020-2022 (USD Million)
Figure 137: Lundbeck Revenue, By Geographical Segments, 2021 (%)
Figure 138: AbbVie Inc. Revenues, 2020-2022 (USD Million)
Figure 139: AbbVie Inc. Revenue, Product Sales by Product Segment, 2022 (%)
Figure 140: AbbVie Inc. Revenue, By Geographical Segments, 2022 (%)
Figure 141: Novartis Revenues, 2020-2022 (USD Million)
Figure 142: Novartis Revenue, By Business Segments, 2022 (%)
Figure 143: Novartis Revenue, By Geographical Segments, 2022 (%)
Figure 144: Amgen, Inc. Revenues, 2020-2022 (USD Million)
Figure 145: Amgen, Inc. Revenues, By Geographic Segments, 2022 (%)
Figure 146: Amgen, Inc. Revenue, By Products, 2022 (%)

List of Tables

Table A1: CGRP Inhibitor studies in pipeline
Table A2: United States CGRP Inhibitor Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A3: United States CGRP Inhibitor Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A4: United States CGRP Inhibitor Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A5: United States CGRP Inhibitor Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A6: United States CGRP Inhibitor Market, By End-User, By Value, 2019-2022 (USD Million)
Table A7: United States CGRP Inhibitor Market, By End-User, By Value, 2023-2029 (USD Million)
Table A8: Canada CGRP Inhibitor Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A9: Canada CGRP Inhibitor Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A10: Canada CGRP Inhibitor Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A11: Canada CGRP Inhibitor Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A12: Canada CGRP Inhibitor Market, By End-User, By Value, 2019-2022 (USD Million)
Table A13: Canada CGRP Inhibitor Market, By End-User, By Value, 2023-2029 (USD Million)
Table A14: Rest of Americas CGRP Inhibitor Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A15: Rest of Americas CGRP Inhibitor Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A16: Rest of Americas CGRP Inhibitor Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A17: Rest of Americas CGRP Inhibitor Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A18: Rest of Americas CGRP Inhibitor Market, By End-User, By Value, 2019-2022 (USD Million)
Table A19: Rest of Americas CGRP Inhibitor Market, By End-User, By Value, 2023-2029 (USD Million)
Table A20: Germany CGRP Inhibitor Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A21: Germany CGRP Inhibitor Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A22: Germany CGRP Inhibitor Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A23: Germany CGRP Inhibitor Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A24: Germany CGRP Inhibitor Market, By End-User, By Value, 2019-2022 (USD Million)
Table A25: Germany CGRP Inhibitor Market, By End-User, By Value, 2023-2029 (USD Million)
Table A26: United Kingdom CGRP Inhibitor Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A27: United Kingdom CGRP Inhibitor Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A28: United Kingdom CGRP Inhibitor Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A29: United Kingdom CGRP Inhibitor Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A30: United Kingdom CGRP Inhibitor Market, By End-User, By Value, 2019-2022 (USD Million)
Table A31: United Kingdom CGRP Inhibitor Market, By End-User, By Value, 2023-2029 (USD Million)
Table A32: France CGRP Inhibitor Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A33: France CGRP Inhibitor Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A34: France CGRP Inhibitor Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A35: France CGRP Inhibitor Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A36: France CGRP Inhibitor Market, By End-User, By Value, 2019-2022 (USD Million)
Table A37: France CGRP Inhibitor Market, By End-User, By Value, 2023-2029 (USD Million)
Table A38: Italy CGRP Inhibitor Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A39: Italy CGRP Inhibitor Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A40: Italy CGRP Inhibitor Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A41: Italy CGRP Inhibitor Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A42: Italy CGRP Inhibitor Market, By End-User, By Value, 2019-2022 (USD Million)
Table A43: Italy CGRP Inhibitor Market, By End-User, By Value, 2023-2029 (USD Million)
Table A44: Spain CGRP Inhibitor Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A45: Spain CGRP Inhibitor Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A46: Spain CGRP Inhibitor Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A47: Spain CGRP Inhibitor Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A48: Spain CGRP Inhibitor Market, By End-User, By Value, 2019-2022 (USD Million)
Table A49: Spain CGRP Inhibitor Market, By End-User, By Value, 2023-2029 (USD Million)
Table A50: Rest of Europe CGRP Inhibitor Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A51: Rest of Europe CGRP Inhibitor Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A52: Rest of Europe CGRP Inhibitor Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A53: Rest of Europe CGRP Inhibitor Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A54: Rest of Europe CGRP Inhibitor Market, By End-User, By Value, 2019-2022 (USD Million)
Table A55: Rest of Europe CGRP Inhibitor Market, By End-User, By Value, 2023-2029 (USD Million)
Table A56: China CGRP Inhibitor Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A57: China CGRP Inhibitor Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A58: China CGRP Inhibitor Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A59: China CGRP Inhibitor Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A60: China CGRP Inhibitor Market, By End-User, By Value, 2019-2022 (USD Million)
Table A61: China CGRP Inhibitor Market, By End-User, By Value, 2023-2029 (USD Million)
Table A62: Japan CGRP Inhibitor Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A63: Japan CGRP Inhibitor Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A64: Japan CGRP Inhibitor Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A65: Japan CGRP Inhibitor Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A66: Japan CGRP Inhibitor Market, By End-User, By Value, 2019-2022 (USD Million)
Table A67: Japan CGRP Inhibitor Market, By End-User, By Value, 2023-2029 (USD Million)
Table A68: South Korea CGRP Inhibitor Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A69: South Korea CGRP Inhibitor Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A70: South Korea CGRP Inhibitor Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A71: South Korea CGRP Inhibitor Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A72: South Korea CGRP Inhibitor Market, By End-User, By Value, 2019-2022 (USD Million)
Table A73: South Korea CGRP Inhibitor Market, By End-User, By Value, 2023-2029 (USD Million)

Table Information

Report Attribute	Details
No. of Pages	230
Published	September 2023
Forecast Period	2024 - 2029
Estimated Market Value ( USD ) in 2024	$ 2.15 Billion
Forecasted Market Value ( USD ) by 2029	$ 5.6 Billion
Compound Annual Growth Rate	21.0%
Regions Covered	Global

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2406EUR$2,450USD£2,007GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€2896EUR$2,950USD£2,417GBP

Scope of the Report

Table of Contents

Table Information

Related Topics

Related Reports

CGRP Inhibitor Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

Migraine Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (Ditans, NSAIDs), By Route Of Administration (Oral, Injectable), By Treatment, By Age Group, By Availability, By Region, And Segment Forecasts, 2024 - 2030

CGRP-Directed Migraine Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, and Product Type

Migraine Drugs Market Report by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region 2024-2032

Migraine Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029